[1] In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli

[2] Application of fluoroquinolone pharmacodynamics

[3] Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network

[4] Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000)

[5] Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men

[6] Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance

[7] Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation

[8] Typhoid fever

[9] The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype choleraesuis

[10] Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)

[11] Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

[12] Additional benefits of GeneXpert MTB/RIF assay for the detection of pulmonary tuberculosis patients with prior exposure to fluoroquinolones

[13] Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones

[14] Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

[15] Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]

[16] Additional benefits of GeneXpert MTB/RIF assay for the detection of pulmonary tuberculosis patients with prior exposure to fluoroquinolones

[17] Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones

[18] Dual Glycation-Inflammation Modulation, DPP-IV and Pancraetic Lipase Inhibitory Potentials and Antiproliferative Activity of Novel Fluoroquinolones.

[19] Removal of aqueous fluoroquinolones with multi-functional activated carbon (MFAC) derived from recycled long-root Eichhornia crassipes: batch and column studies.

[20] Rapid and simultaneous determination of three fluoroquinolones in animal-derived foods using excitation-emission matrix fluorescence coupled with second-order calibration method

[21] SYNTHESIS AND ANTIMICROBIAL ACTIVITIES OF NEW 1,2,4- TRIAZOLES, MANNICH BASES, CONAZOLES, AND FLUOROQUINOLONES

[22] Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities

[23] A nanofiber mat prepared from sulfonated polyaniline for solid-phase extraction of fluoroquinolones from water and biological fluids prior to their quantitation by UPLC-MS/MS.

[24] Rate constants of hydroxyl radicals reaction with different dissociation species of fluoroquinolones and sulfonamides: Combined experimental and QSAR studies

[25] Susceptibility of Antimicrobial-Resistant Urinary Escherichia coli Isolates to Fluoroquinolones and Nitrofurantoin

[26] Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!

[27] Synergy of Fluoroquinolones with Other Antimicrobial Agents

[28] Impact of Fluoroquinolones on the Gastrointestinal Flora

[29] Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades

[30] Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network

[31] Use of Fluoroquinolones for Intracellular Pathogens

[32] Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance

[33] Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin

[34] kinetic spectrophotometric method for the determination of some fourth generation fluoroquinolones in bulk and in pharmaceutical formulations

[35] emergence of an extensively drug-resistant salmonella enterica serovar typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins

[36] Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB

[37] Evaluation of genetic mutations associated with phenotypic resistance to Fluoroquinolones, Bedaquiline, and Linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis.